This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
J&J's Darzalex Gets FDA Nod for First-Line Multiple Myeloma
by Zacks Equity Research
Johnson & Johnson's (JNJ) label expansion application, seeking approval for Darzalex+Revlimid to treat transplant ineligible newly diagnosed patients with multiple myeloma, receives FDA approval.
AbbVie Announces Lifting of FDA's Partial Hold on CANOVA Study
by Zacks Equity Research
AbbVie (ABBV) receives encouraging news as FDA lifts partial clinical hold on a late-stage study evaluating Venclexta in relapsed/refractory multiple myeloma.
Pharma Stock Roundup: PFE to Buy ARRY, RHHBY, MRK, AZN Drugs Get Regulatory Nod
by Kinjel Shah
Pfizer (PFE) announces definitive deal buy Array BioPharma. Merck (MRK), Roche (RHHBY) and AstraZeneca (AZN) win approvals for new drugs/line extensions.
Sanofi Partners Google to Build Healthcare Innovation Lab
by Zacks Equity Research
Sanofi (SNY) signs a partnership pact with Google to develop a new virtual healthcare innovation lab for modernizing future medicines and healthcare services with sophisticated data technologies.
Roche's Rozlytrek Gets Approval in Japan for Solid Tumors
by Zacks Equity Research
Roche's (RHHBY) oncology portfolio gets a boost with the approval of Rozlytrek for neurotrophic tyrosine receptor kinase fusion-positive, advanced recurrent solid tumors.
Bayer to Invest 5 Billion Euros in Weedkiller Research
by Zacks Equity Research
Bayer (BAYRY) announces that it will invest 5 billion euros in developing new weedkillers amid lawsuits claiming its glyphosate-based weedkillers cause cancer.
AstraZeneca Gives Detailed Data From Calquence Leukemia Study
by Zacks Equity Research
AstraZeneca's (AZN) Calquence monotherapy prolongs progression-free survival significantly in relapsed or refractory CLL patients compared to Roche's Rituxan.
Pharma Stock Roundup: MRK Buys Small Cancer Biotech, RHHBY, MRK Drugs Get FDA Nod
by Kinjel Shah
Key developments of the week include Merck's (MRK) deal to buy Tilos Therapeutics and FDA approval for Roche's (RHHBY) polatuzumab vedotin and Merck's Keytruda.
Amgen/Allergan Get FDA Nod for Herceptin Biosimilar Kanjinti
by Zacks Equity Research
FDA approves Amgen (AMGN) and Allergan's Kanjiniti, a biosimilar version of Roche's (RHHBY) breast cancer drug, Herceptin.
Mallinckrodt Presents Encouraging Data on Acthar Gel for RA
by Zacks Equity Research
Mallinckrodt (MNK) reports encouraging results from a phase IV study on Acthar for RA at the EULAR.
Roche Reports Positive Data on Rituxan for Pemphigus Vulgaris
by Zacks Equity Research
Roche (RHHBY) announces positive data on rheumatic diseases drug, Rituxan, for pemphigus vulgaris.
Roche's Rituxan Gets Priority Review for Blood Disorder
by Zacks Equity Research
Roche (RHHBY) gets Priority Review status from the FDA for Rituxan in children with two rare blood vessel disorders.
Boost Your Portfolio's Health With These 3 Big Drug Stocks
by Kinjel Shah
The large-cap pharma industry is doing well in 2019. Here are three stocks from the space that investors may consider betting on.
Insys Down on Bankruptcy News Amid Increasing Legal Expenses
by Zacks Equity Research
Insys (INSY) crashes as it files for bankruptcy protection amid rising legal settlement dues.
Roche's Polivy Gets FDA Nod, Gazyva Meets Goals in Phase II
by Zacks Equity Research
Roche's (RHHBY) hematology portfolio gets a boost as FDA approves Polivy for DLBCL, and lymphoma drug, Gazyva, meets goals in a phase II study.
The Zacks Analyst Blog Highlights: Bristol Myers, Merck, Roche, Lilly and AstraZeneca
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Bristol Myers, Merck, Roche, Lilly and AstraZeneca
Roche Receives FTC Request for Further Data on Spark Buyout
by Zacks Equity Research
Roche (RHHBY) gets additional information request from FTC for the pending Spark acquisition.
AstraZeneca's Calquence Meets Endpoint in 2nd CLL Study
by Zacks Equity Research
AstraZeneca's (AZN) lymphoma drug, Calquence, meets the primary endpoint and a key secondary one in a phase III study for the first-line treatment of chronic lymphocytic leukaemia.
Pharma Stock Roundup: ASCO Update, FDA Nod for LLY's Emgality for Cluster Headache
by Kinjel Shah
Pharma bigwigs present data from cancer studies at ASCO. Lilly's (LLY) CGRP Emgality gets FDA approval for episodic cluster headache in adults.
Mallinckrodt Down After Agreement with DOJ for Litigation
by Zacks Equity Research
Mallinckrodt (MNK) expects to pay $15.4 million to DOJ in relation with the Questcor litigation.
Was ASCO Quieter for Big Drug/Biotech Stocks This Year?
by Kinjel Shah
The annual meeting of the American Society of Clinical Oncology (ASCO) in Chicago sees cancer data presentations from several drug/biotech companies about the latest developments in treating cancer.
Blueprint Medicines to File NDA for Avapritinib With FDA
by Zacks Equity Research
Blueprint Medicines' (BPMC) excessive confidence in partners for revenue recognition is still a huge cause for concern.
Pfizer to Launch Several Drugs Despite Generic Headwinds
by Zacks Equity Research
Pfizer (PFE) looks well positioned to launch several breakthrough innovative medicines in the next five years amid loss of exclusivity headwinds.
Amgen's KRAS Inhibitor Shows Impressive Anti-Tumor Activity
by Zacks Equity Research
At ASCO, Amgen (AMGN) presented encouraging initial data set for AMG 510, its novel investigational KRAS inhibitor for solid tumor.
Merck's Antibiotic Zerbaxa Gets FDA Nod for New Indication
by Zacks Equity Research
Merck (MRK) gets FDA approval for antibacterial medicine, Zerbaxa for hospital-acquired bacterial pneumonia and ventilator-associated bacterial pneumonia (HABP/VABP)